

**Johnson & Johnson and Subsidiaries**  
**Reconciliation of Non-GAAP Financial Measures**

<i>(Dollars in Millions Except Per Share Data)</i>	Fourth Quarter		% Incr. / (Decr.)	Twelve Months		% Incr. / (Decr.)
	2012	2011		2012	2011	
Earnings before provision for taxes on income - as reported	\$ 3,100	318	874.8 %	\$ 13,775	12,361	11.4 %
Net litigation loss (gain)	471	2,656		1,229	3,310	
In-process research and development	55	14		1,163	14	
Synthes integration/transaction costs and currency related	406	277		1,028	491	
Intangible asset write-downs and other adjustments	-	-		909	-	
DePuy ASR™ Hip program	83	412		110	521	
Restructuring	-	(20)		-	656	
Earnings before provision for taxes on income - as adjusted	<u>\$ 4,115</u>	<u>3,657</u>	<u>12.5 %</u>	<u>\$ 18,214</u>	<u>17,353</u>	<u>5.0 %</u>
Net Earnings attributable to Johnson & Johnson - as reported	\$ 2,567	218	1,077.5 %	\$ 10,853	9,672	12.2 %
Net litigation loss (gain)	371	2,239		1,052	2,745	
In-process research and development	59	11		743 (1)	11	
Synthes integration/transaction costs and currency related	306	338		899	477	
Intangible asset write-downs and other adjustments	-	-		701	-	
DePuy ASR™ Hip program	73	336		97	426	
Restructuring	-	(13)		-	536	
Net Earnings attributable to Johnson & Johnson - as adjusted	<u>\$ 3,376</u>	<u>3,129</u>	<u>7.9 %</u>	<u>\$ 14,345</u>	<u>13,867</u>	<u>3.4 %</u>
Diluted Net Earnings per share attributable to Johnson & Johnson - as reported	\$ 0.91	0.08	1,037.5 %	\$ 3.86	3.49	10.6 %
Net litigation loss (gain)	0.13	0.81		0.37	0.99	
In-process research and development	0.02	-		0.27	-	
Synthes integration/transaction costs and currency related	0.11	0.12		0.32	0.17	
Intangible asset write-downs and other adjustments	-	-		0.25	-	
DePuy ASR™ Hip program	0.02	0.12		0.03	0.16	
Restructuring	-	-		-	0.19	
Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted	<u>\$ 1.19</u>	<u>1.13</u>	<u>5.3 %</u>	<u>\$ 5.10</u>	<u>5.00</u>	<u>2.0 %</u>

(1) Amount includes third quarter in-process research and development charge of \$679M related to bapineuzumab IV offset by \$339M reported as net loss attributable to noncontrolling interest

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.